A Multicenter, Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS-7249 in Patients With Hyperlipidemia
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The study is being conducted to evaluate the efficacy and safety of HRS-7249 for patients with hyperlipidemia, and to explore the reasonable dosage of HRS-7249 for patients with hyperlipidemia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Able and willing to provide a written informed consent.
• Age ≥ 18 years old and \< 80 years old.
• Male or female.
Locations
Other Locations
China
Shanghai Chest Hospital
RECRUITING
Shanghai
Contact Information
Primary
Chanjuan Deng
chanjuan.deng@hengrui.com
+86-0518-82342973
Time Frame
Start Date: 2025-08-12
Estimated Completion Date: 2027-01
Participants
Target number of participants: 200
Treatments
Experimental: HRS-7249 Group
Placebo_comparator: Sodium Chloride Injection Group
Related Therapeutic Areas
Sponsors
Leads: Fujian Shengdi Pharmaceutical Co., Ltd.